US Patent Application No: 2004/0248,781

Number of patents in Portfolio can not be more than 2000

Therapeutic method for reducing angiogenesis

Stats

ATTORNEY / AGENT: (SPONSORED)
 

Importance

Loading Importance Indicators... loading....

Abstract

A method of controlling or treating an angiogenic dependent condition in a mammal, preferably in a human by administering an anti-angiogenic molecule such as an angiogenesis growth factor antagonist, and a chemotherapeutic agent in amounts and frequencies effective, in combination, to produce a regression or arrest of said condition while minimizing or preventing significant toxicity of the chemotherapeutic agent. Also a kit for controlling or treating an angiogenic dependent condition in a mammal, preferably in a human, comprising an anti-angiogenic molecule, such as an angiogenesis growth factor antagonist, and a chemotherapeutic agent in amounts effective, in combination, to produce a regression or arrest of said condition while minimizing or preventing significant toxicity of the chemotherapeutic agent.

Loading the Abstract Image... loading....

First Claim

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
SUNNYBROOK HEALTH SCIENCES CENTRETORONTO, ON43

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Kerbel, Robert Toronto, CA 5 16

Patent Citation Ranking

Forward Cites

Patent Info (Count) # Cites Year
 
DYAX CORP. (7)
7,211,240 Multivalent constructs for therapeutic and diagnostic applications 8 2003
7,261,876 Multivalent constructs for therapeutic and diagnostic applications 4 2003
7,666,979 Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same 0 2004
7,871,610 Antibodies to Tie1 ectodomain 1 2005
7,485,297 Method of inhibition of vascular development using an antibody 5 2005
7,854,919 Multivalent constructs for therapeutic and diagnostic applications 0 2007
7,910,088 Multivalent constructs for therapeutic and diagnostic applications 0 2007
 
HUMAN GENOME SCIENCES, INC. (4)
7,223,724 Use of vascular endothelial growth factor to treat photoreceptor cells 8 2000
7,273,751 Vascular endothelial growth factor-2 7 2001
7,208,582 Vascular endothelial growth factor 2 13 2002
7,524,501 Methods of treating an injury to, or disorder of, the eye involving photoreceptor proliferation by administering VEGF2 antibodies 3 2005
 
ABRAXIS BIOSCIENCE, LLC (3)
8,034,375 Combinations and modes of administration of therapeutic agents and combination therapy 0 2006
7,758,891 Combinations and modes of administration of therapeutic agents and combination therapy 1 2008
8,268,348 Combinations and modes of administration of therapeutic agents and combination therapy 0 2011
 
BRACCO SUISSE SA (2)
7,794,693 Targeting vector-phospholipid conjugates 0 2006
7,985,402 Targeting vector-phospholipid conjugates 0 2007